Drug Delivery Technology - Revolutionizing Cancer Therapies

Description: "One of the biggest issues with current cancer therapies is that whilst most therapies procure quality of life they kill both healthy and tumor cells. This offers drug delivery specialists a challenge and opportunity to increase the therapeutic index and ultimately deliver targeted therapies to cancer cells whilst minimizing off-target side effects.” Dr Cheryl Barton.

Whilst significant advances have been made in the treatment of many cancer subtypes, the therapies currently available often require regular visits to the hospital or clinic to receive radioactive therapy or intravenous chemotherapy which are highly toxic, may lead to drug resistance and are poorly tolerated due to limited-tumor specificity leading to many unwanted side-effects and poor compliance.

While the pharmaceutical industry continues to find innovative ways to treat cancer, drug delivery specialists have the task of making sure those treatments reach the correct site in the body in the required quantities and at the right time. The Holy Grail in delivering cancer therapies is the development of a technology platform which targets the therapy only to the tumor, leaving normal cells undamaged. In an ideal world, orally active targeted therapies would be available.

The following report summarizes the latest developments in cancer drug development and analyzes some of the most promising solutions which drug delivery companies are providing in order to address this unmet clinical need.

-Gain an in-depth understanding of the technology landscape for active & passive targeting platforms, including injectable & oral systems
- Assess the options available for delivering anticancer compounds now & in the future
- Gauge the current & future technology requirements of pharma & biotech companies developing oncology products
- Analyze how the market is evolving & the influence that drug delivery may have on pharma oncology pipelines
- Identify key pharma & delivery companies focusing on the improved delivery of existing & novel anticancer agents
- Highlight alliances between delivery companies & pharma, and recent market activity
- Evaluate where progress has been made in the delivery of potential new oncology products

Eight Questions This Note Answers:

1. How will the drug delivery technology drivers change in the cancer arena in the next decade and beyond?
2. What are the key delivery technologies in the oncology field?
3. When are products which utilise these key delivery technologies likely to reach the market?
4. Which companies are the winners in each technology category?
5. How are drug delivery technologies evolving to meet the demands of the oncology market?
6. Where are the market opportunities now and in the future?
7. What do we predict will be the value of the cancer drug delivery market each year until 2012, in 2015 and in 2020?
1 The cancer market and drug delivery technology opportunities

1.1 Introduction
1.2 Overview of the market
1.2.1 Market size
1.2.2 Key pharma players
1.2.3 Growth areas for drug delivery
1.3 Product pipeline
1.3.1 Key cancer subtypes
1.3.2 Drug delivery improving probability

2 Market drivers and opportunities for drug delivery technologies

3 Key drug delivery companies and academic researchers in cancer research

4 Current drug delivery issues and opportunities in chemotherapy

4.1 Active targeting
4.2 Passive targeting
4.3 Orally active targeting

5 Active targeted drug delivery platforms

5.1 Tumor-specific antigens and receptors as carriers
5.1.1 Case Study: Avidimer Nanoparticles/ATI-001 (Avidimer Therapeutics)
5.1.2 Case Study: IL13-PE38 (NeoPharm/Nippon Kayaku)
5.2 Peptide-based drug delivery
5.2.1 Case Study: Vectocell Technology/DTS-108 (Diatos)
5.2.2 Case Study: TSP Technology/DTS-201 (Diatos)
5.3 Antibody-based drug delivery
5.3.1 Case Study: radio-imunotherapy/IMMU-107 (Immunomedics/UCB)
5.3.2 Case Study: antibody drug conjugates/SGN-35 & SGN-75 (Seattle Genetics)
5.3.3 Case Study: tumor-activated prodrug (TAP)/HuN901-DM (ImmunoGen) and Trastuzumanb-MCC-DM1 (ImmunoGen/Genentech)
5.4 Second-generation antibody fragments for drug delivery
5.4.1 Case Study: single-chain antibodies (SCAs) (Enzon)
5.4.2 Case Study: SS1(dsFv) PE38 (NeoPharm)
5.5 ADEPT
5.5.1 Case Study: ADEPT platform/ZD2767P (academic institutions)
5.6 Nucleic acid-based drug delivery
5.6.1 Case Study: Aptamer-conjugated nanoparticles (Harvard Medical School/MIT)
5.5 Our Opinion on Active Targeting Technologies

6 Passive targeted platforms

6.1.1 Case Study: Nanoparticle albumin bound formulation/Abraxane (Abraxis BioSciences/AstraZeneca)
6.2 Liposomal encapsulation
6.2.1 Case Study: NeoLipid technology/LE-SN38 (NeoPharm)
6.2.2 Case Study: STEALTH liposome technology/Doxil (ALZA)
6.2.3 Case Study: sphingosome technology (INEX/Hana Biosciences)
6.3 Synthetic polymers
6.3.1 Case Study: Platinate polymers/ProLindac (Access Pharmaceuticals)
6.3.2 Case Study: Polyglutamate drug delivery/Xyotax (Cell Therapeutics)
6.4 Pegylation
6.4.1 Case Study: Customized Linker TechnologyTM/PEG-SN38 (Enzon)
6.5 Second-generation smart bioerodible polymer systems
6.5.1 Case Study: ReGel® polymer technology/DTS-301 (Protherics/Diatos)
6.6.1 Case Study: Bioerodible polymers/Locterion (OctoPlus/Biolex)
6.6 Our opinion on passive targeting technologies

7 Oral Targeted Drug Delivery Platforms

7.1.1 Case Study: eligen technology/oral gallium (Emisphere Technologies/Genta)
7.1.2 Case Study: Contramid (Labopharm)
7.1.3 Case Study: Polymeric Nano-Delivery System (Labopharm/Debiopharm)
7.1.4 Case Study: BiontransportTM Nanomedicine/SP1049C (Supratek)
7.1.5 Case Study: Lipid Polymer Micelle (LPM™) system/LPM Leuprolide (DOR BioPharma)
7.1.6 Case Study: Cobalamin™-mediated drug delivery (Access Pharmaceuticals)

7.2 Our opinion on oral drug delivery technologies in cancer

8. Market trends in drug delivery in cancer

8.1 Key drug delivery players in the oncology arena
8.2 Recent partnerships and acquisitions
8.2.1. Specialist technology and cross-platform providers
8.2.2. Emerging specialty pharma companies
8.2.3. Spin-off companies
8.2.4. Pharma acquisitions
8.3 Market trends now 2006-2012
8.3.1 Historical drug delivery market 2000-2005
8.3.2 Global drug delivery market 2006-2012
8.3.3 Global advanced cancer drug delivery market 2006-2012
8.3.4 Pharma drivers and drug delivery trends by 2012
8.4 Market by 2020
8.4.1 Global advanced drug delivery market by 2020
8.4.2 Global advanced cancer drug delivery by 2020
8.4.3 Pharma drivers and drug delivery trends by 2020
8.4.4 Drug delivery trends by 2020

9 Summary & Conclusions

10 Bibliography

11 Acknowledgements

List of Tables:
List of Figures

Figure 1.1: Global Oncology Market Sales 2006
Figure 1.2: Leading oncology brands 2006
Figure 1.3: Global oncology market players and leading brands 2006
Figure 1.4: Global oncology sales 2006 – cancer subtypes
Figure 1.5: Oncology medicines in development 2006
Figure 2.1: Drug delivery opportunities in cancer
Figure 2.2: Cancer patients still under treatment
Figure 5.1: ATI-001 Avidimer Therapeutics Smart drug
Figure 5.2: Application of antibody-based targeted therapy
Figure 5.3: Schematic of ImmunoGen's TAP technology
Figure 5.4: Schematic of mAb and SCA
Figure 5.5 Schematic of ADEPT theory
Figure 5.6 Schematic of A) aptamer-conjugated nanoparticles and B) scanning electron microscopy image of docetaxel encapsulated nanoparticles
Figure 6.1: Nanoparticle albumin-bound (nab) platform technology
Figure 6.2: Clinical efficacy of Abraxane versus Taxol
Figure 6.3: Pharmacokinetics of STEALTH® liposomes in preclinical and clinical studies
Figure 6.4: Specificity and enhanced activity of sphingosomal vincristine
Figure 6.5: Access Pharmaceuticals' nanoparticle polymer platform technology
Figure 6.6: Daunorubicin with Polymer & Cobalamin-targeted
Figure 6.7: PolyActive controlled release of interferon alpha & its application for therapeutic proteins
Figure 7.1: Cobalamin™-mediated oral delivery
Figure 8.1: Progression of oncology products fuelled by drug delivery by 2012
Figure 8.2: Progression of oncology products fuelled by drug delivery by 2020

List of tables

Table 1.1: Inherent risks of drug development
Table 2.1: US patent expiration of leading oncology brands
Table 3.1: Leading drug delivery technology companies in the cancer arena
Table 3.2: Leading academic research laboratories in cancer drug delivery technology
Table 5.1: Tumor-specific antigens for drug delivery
Table 5.2: Leading drug delivery companies & academic institutes evaluating active targeted delivery
Table 5.3: Immunotherapeutic monoclonal antibodies approved to treat cancer
Table 5.4: Antibody-based therapies in development to treat cancer
Table 5.5: Summary of antibody fragments and engineered variants
Table 5.6: Antibody-based therapies under evaluation by NCI
Table 6.1: Leading companies & academic research groups in polymer development for drug delivery
Table 6.2: Commercially available polymers for drug delivery
Table 6.3: FDA approved PLA/PLGA cancer products
Table 8.1: Summary of leading oncology-focused drug delivery companies
Table 8.2: Summary of recent alliances, agreements and acquisitions with drug delivery companies
Table 8.3: Forecast of global pharmaceutical market and drug delivery market (2000-2005)
Table 8.4: Forecast of global drug delivery market 2006-2012
Table 8.5: Forecasts of approved drug delivery-driven cancer products 2006-2012 (US$m)
Table 8.6: Forecasts of pipeline drug delivery driven oncology products 2006-12 (US$m)
Table 8.7: Forecast of drug delivery market 2012-2020 (US$ billion)

Ordering: Order Online - http://www.researchandmarkets.com/reports/682979/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Drug Delivery Technology - Revolutionizing Cancer Therapies
Web Address: http://www.researchandmarkets.com/reports/682979/
Office Code: SCD23GYA

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1139</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4555</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 28470</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr [ ]  Mrs [ ]  Dr [ ]  Miss [ ]  Ms [ ]  Prof [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________  
Job Title: ___________________________  
Organisation: ___________________________  
Address: ___________________________  
City: ___________________________  
Postal / Zip Code: ___________________________  
Country: ___________________________  
Phone Number: ___________________________  
Fax Number: ___________________________  

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp